The incidence of liver cancer in China is very high, because liver cancer is difficult to find in the early stage of the disease. Once the diagnosis is often in the middle and late stages, the optimal treatment time is often missed. The traditional treatment for liver cancer is surgery, radiotherapy and chemotherapy, etc. However, such treatment methods generally have a relatively high recurrence rate, and the survival rate of patients is relatively low. To prevent recurrence and metastasis of liver tumors, cell immunotherapy can be tried at this time.
Due to the limitation of liver meall size, growth location, and relationship with the position of large blood vessels and biliary tract, some patients with special small liver cancer, huge liver tumor, and middle-advanced liver cancer with multiple metastatic lesions often lose the opportunity for surgery.
However, for these patients, the expert’s approach is to first use argon-helium ultra-cold knife minimally invasive treatment, through physical freezing and thawing to destroy the cell structure of tumor tissue in a short period of time, promote tumor tissue necrosis and close tumor small blood vessels. At the same time, combined with interventional therapy, embolization of tumor large vessels and local high-concentration chemotherapy, the combination of the two therapies can inhibit the growth of liver cealla ailse and eliminate tumor lesions in a short period of time.
In general, most of the primary ailsí ae are large undetectable liver cancers, which are accompanied by tumor thrombi in the internal and external portal vein system. The recurrence rate within one year after radiotherapy and chemotherapy is as high as 60%, and the 3-year survival rate is less than 30%. Therefore, the most important thing for liver cancer surgery is to prevent recurrence, but traditional radiotherapy and chemotherapy have large side effects, which can easily lead to liver cirrhosis and even liver function damage.
Modh cóireála réasúnta nua-díolúine cille bitheolaíoch
(cealla CIK) tionchar suntasach ar ailse ae chun cinn. Is féidir leis an teiripe seo cabhrú leis na cealla ailse atá fágtha i gcorp an othair a ghlanadh, feidhm imdhíonachta an othair maidir le cealla ailse a aithint agus a mharú a athbhunú, agus mar sin metastasis meall a chosc agus a rialú.
Is cealla marfacha cítocine-spreagtha iad cealla CIK, ar cealla mononuclear iad atá scoite amach ó fhuil imeallach, smeara nó fuil chorda imleacáin. Tar éis tréimhse áirithe ama sa tsaotharlann, déantar iad a tharlú, a iomadú, agus ansin iad a ath-insileadh isteach san othar chun an fhuil a mharú go díreach, déanann cealla meall sa limfe freisin feidhm imdhíonachta an othair a rialáil agus a fheabhsú.
De réir staitisticí cliniciúla, téann 9 n-othar le hailse ae céim 4 faoi níos mó ná 3 thimthriall imdhíonteiripe cille tar éis máinliachta, rud a d'fhéadfadh cosc a chur ar atarlú ailse ae tar éis máinliachta. Is é an meán-am marthanais tar éis cóireála ná 20 mí, agus níl an ráta atarlaithe laistigh de 1 bhliain ach 22.2%, agus feabhsaítear comharthaí míchompord an chuid is mó d'othair.
An tuiscint thuas simplí a chosc atarlú siadaí ae agus metastasis, is féidir leat triail imdhíonteiripe cille, tá immunotherapy cille modh réasúnta nua de chóireáil ailse, mar shampla immunotherapy cille bitheolaíochta, is féidir cabhrú le hothair a bhaint cealla ailse iarmharach sa chorp, chomh maith le díolúine. Tá éifeacht ag teiripe cealla ailse a aithint agus a mharú, rud a chuireann cosc a thuilleadh ar scaipeadh agus metastasis siadaí.
